Azenta Earnings Call: Reset Outlook Amid Turnaround

Azenta, Inc. ((AZTA)) has held its Q2 earnings call. Read on for the main highlights of the call.

Azenta’s latest earnings call painted a mixed picture, balancing encouraging operational progress and resilient recurring revenue against weaker organic growth, margin pressure, and sizable goodwill impairments. Management emphasized that execution is improving and core demand drivers remain intact, but also acknowledged that profitability and growth expectations for the next couple of years need to be reset.

Recurring revenue resilience in biorepositories

Azenta continued to lean on its recurring revenue engine, with sample repository and biorepository solutions growing at a high single-digit pace and now representing roughly 40% of the Sample Management Solutions segment. This strength supported steady demand for related services, consumables, and instruments, helping to cushion the impact from softer capital equipment spending.

Operational execution gains from ABS

The company highlighted notable operational improvements under the Azenta Business System, particularly in delivery performance and lab turnaround times. On-time delivery in consumables and instruments improved sharply from about 15% to roughly 70%, while Lightning RNA-Seq turnaround was cut from roughly 20 days to about five days, which management framed as a key market differentiator.

Balance sheet strength and cash generation

Azenta closed the quarter with $565 million in cash, cash equivalents, and marketable securities and no debt, giving the company substantial financial flexibility. Free cash flow was a modest but positive $5 million on about $7 million of capex, allowing room for continued investment and selective acquisitions even as earnings come under pressure.

Strategic acquisition of UK Biocentre

Management underscored the strategic rationale behind the March acquisition of UK Biocentre, which added around $1 million of revenue in the quarter. Beyond the near-term contribution, the deal expands Azenta’s biorepository footprint and creates a stronger operational hub in Europe, which the company expects to leverage for future growth and service delivery.

Cost actions and leadership changes

To address margin pressure and execution gaps, Azenta has launched partial restructuring efforts aimed at tightening costs and sharpening engineering focus. The actions are expected to yield about $7 million of annualized savings, with roughly $3 million realized this year, alongside a reorganization of engineering into three focused teams and the appointment of Trey Martin to lead the Multiomics transformation.

Revenue softness and segment divergence

Despite some operational wins, the top line disappointed, with Q2 revenue of $145 million up 1% reported but down 3% organically once FX and the UK Biocentre are excluded. Multiomics revenue was flat reported and down about 2% organically, while SMS rose 2% reported but fell roughly 3% organically, reflecting weakness in capital-intensive products and a sluggish North American demand backdrop.

EBITDA and EPS under pressure

Profitability came under visible strain as adjusted EBITDA fell to $7.8 million, equating to a 5.4% margin and a roughly 320-basis-point drop versus last year. Non-GAAP EPS slipped to a loss of $0.04, reflecting lower volumes, weaker fixed-cost absorption, and ongoing investment in sales, R&D, and marketing to support longer-term growth.

Gross margin compression and quality costs

Consolidated gross margin declined to 44.3%, down about 110 basis points year over year, with particular pressure in the Multiomics segment, where margin fell to 40.2%. Management pointed to weaker North American volumes, unfavorable regional mix, a noncash inventory charge, and around $2 million in quality-related rework tied to automated storage remediation as key drivers.

Heavy goodwill impairments hit reported results

The quarter’s reported results were further clouded by significant noncash goodwill impairments totaling roughly $149 million, split between Multiomics and SMS. These write-downs stem from a reduced near-term outlook, the sustained decline in Azenta’s stock price, and broader macro and geopolitical uncertainties, and do not impact the company’s cash position.

Automated storage issues and order pushouts

Automated storage quality problems forced Azenta to undertake remediation work, originally affecting about 18 stores and now narrowed to three remaining installations expected to be completed by the end of Q3. The disruption, coupled with customers delaying multimillion-dollar cryogenic and automated storage orders, weighed on near-term order conversion and reduced the company’s visibility into capital equipment volumes.

B Medical divestiture uncertainty and loss

The planned divestiture of B Medical has become another headwind, as the buyer’s inability to secure financing has delayed closing. Azenta recorded an additional $6 million noncash loss related to assets held for sale and signaled ongoing uncertainty around timing, adding another layer of noise and distraction to reported financials.

Commercial challenges and North America weakness

Within Multiomics, the company acknowledged commercial execution gaps in North America, including sales rep turnover and ramp issues that weighed on bookings. Combined with persistent market caution, these problems hurt fixed-cost absorption and highlighted the need for better commercial discipline, which management says is a central focus of its current turnaround efforts.

Guidance reset and path to gradual improvement

Azenta reset its fiscal 2026 outlook, now projecting reported revenue of $603 million to $621 million, with organic revenue ranging from down about 2% to up 1% and adjusted EBITDA margin expected to be down roughly 125 basis points to flat year over year. The company anticipates low-single-digit organic growth in Q3 and a low-single-digit decline in Q4 against a tough comparison, alongside sequential margin gains into the low-double-digit range in Q3 and further improvement in Q4, while free cash flow is now expected to rise a more modest 10%–15%.

The call left investors weighing tangible operational progress and a strong balance sheet against a reset growth algorithm and lingering execution and demand risks. Azenta’s management is clearly in repair mode, tightening costs, fixing quality issues, and reshaping commercial strategy, but the pace of recovery and the ability to reaccelerate organic growth remain key questions for the stock over the next several quarters.